{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:52:07Z","timestamp":1740135127134,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Mega-Projects of National Science Research for the 13th Five-Year Plan","award":["2018ZX10721102"],"award-info":[{"award-number":["2018ZX10721102"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To assess transmitted drug resistance (TDR) to tenofovir (TDF)\/emtricitabine (FTC), using as pre-exposure prophylaxis, among newly diagnosed human immunodeficiency virus-1 (HIV-1)-infected residents in Shenyang city, northeast China.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Demographic and epidemiological information of all newly diagnosed HIV-1 infected residents in Shenyang city from 2016 to 2018 were anonymously collected from the local HIV epidemic database. HIV-1 <jats:italic>pol<\/jats:italic> sequences were amplified from RNA in cryopreserved plasma samples and sequenced directly. Viral subtypes were inferred with phylogenetic analysis and drug resistance mutations (DRMs) were determined according to the Stanford HIVdb algorithm. Recent HIV infection was determined with HIV Limiting Antigen avidity electro immunoassay.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 2176 sequences (92.4%, 2176\/2354) were obtained; 70.9% (1536\/2167) were CRF01_AE, followed by CRF07_BC (18.0%, 391\/2167), subtype B (4.7%, 102\/2167), other subtypes (2.6%, 56\/2167), and unique recombinant forms (3.8%, 82\/2167). The prevalence of TDR was 4.9% (107\/2167), among which, only 0.6% (13\/2167) was resistance to TDF\/FTC. Most of these subjects had CRF01_AE strains (76.9%, 10\/13), were unmarried (76.9%, 10\/13), infected through homosexual contact (92.3%, 12\/13), and over 30\u2009years old (median age: 33). The TDF\/FTC DRMs included K65R (8\/13), M184I\/V (5\/13), and Y115F (2\/13). Recent HIV infection accounted for only 23.1% (3\/13). Most cases were sporadic in the phylogenetic tree, except two CRF01_AE sequences with K65R (Bootstrap value: 99%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The prevalence of TDR to TDF\/FTC is low among newly diagnosed HIV-infected cases in Shenyang, suggesting that TDR may have little impact on the protective effect of the ongoing <jats:italic>CROPrEP<\/jats:italic> project in Shenyang city.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06312-3","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T08:03:06Z","timestamp":1625817786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transmitted drug resistance to Tenofovir\/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018"],"prefix":"10.1186","volume":"21","author":[{"given":"Zhen","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghui","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1427-8428","authenticated-orcid":false,"given":"Xiaoxu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"key":"6312_CR1","unstructured":"In: Guidance on Pre-Exposure Oral Prophylaxis (PrEP) for Serodiscordant Couples, Men and Transgender Women Who Have Sex with Men at High Risk of HIV: Recommendations for Use in the Context of Demonstration Projects. edn. Geneva; 2012."},{"key":"6312_CR2","unstructured":"Smith DK, Grant RM, Weidle PJ, Lansky A, Fenton KAJJTJotAMA: Interim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. 2011;305(11):1089\u201391."},{"issue":"4","key":"6312_CR3","first-page":"425","volume":"25","author":"Y Xinyu","year":"2019","unstructured":"Xinyu Y. Practice and challenges of HIV pre-exposure prophylaxis and post-exposure prophylaxis. Chi J AIDS STD. 2019;25(4):425\u20138.","journal-title":"Chi J AIDS STD"},{"key":"6312_CR4","unstructured":"In: Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. edn. Geneva; 2015."},{"issue":"2","key":"6312_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/01.NAJ.0000654292.06762.bd","volume":"120","author":"DS Aschenbrenner","year":"2020","unstructured":"Aschenbrenner DS. Descovy approved for HIV Prexposure prophylaxis. Am J Nurs. 2020;120(2):20\u20131. https:\/\/doi.org\/10.1097\/01.NAJ.0000654292.06762.bd.","journal-title":"Am J Nurs"},{"issue":"16","key":"6312_CR6","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1097\/QAD.0000000000001627","volume":"31","author":"E Hoornenborg","year":"2017","unstructured":"Hoornenborg E, Krakower DS, Prins M, Mayer KH. Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries. Aids. 2017;31(16):2179\u201391. https:\/\/doi.org\/10.1097\/QAD.0000000000001627.","journal-title":"Aids"},{"issue":"3","key":"6312_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.2010.1004","volume":"304","author":"MA Thompson","year":"2010","unstructured":"Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the international AIDS society-USA panel. JAMA. 2010;304(3):321\u201333. https:\/\/doi.org\/10.1001\/jama.2010.1004.","journal-title":"JAMA"},{"issue":"5","key":"6312_CR8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/01.aids.0000216363.36786.2b","volume":"20","author":"SY Rhee","year":"2006","unstructured":"Rhee SY, Kantor R, Katzenstein DA, Camacho R, Morris L, Sirivichayakul S, et al. HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS. 2006;20(5):643\u201351. https:\/\/doi.org\/10.1097\/01.aids.0000216363.36786.2b.","journal-title":"AIDS"},{"issue":"6","key":"6312_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40265-019-01108-x","volume":"79","author":"KM Gibas","year":"2019","unstructured":"Gibas KM, van den Berg P, Powell VE, Krakower DS. Drug resistance during HIV pre-exposure prophylaxis. Drugs. 2019;79(6):609\u201319. https:\/\/doi.org\/10.1007\/s40265-019-01108-x.","journal-title":"Drugs"},{"issue":"1","key":"6312_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/QAD.0000000000002394","volume":"34","author":"JM Fogel","year":"2020","unstructured":"Fogel JM, Sivay MV, Cummings V, Wilson EA, Hart S, Gamble T, et al. HIV drug resistance in a cohort of HIV-infected MSM in the United States. Aids. 2020;34(1):91\u2013101. https:\/\/doi.org\/10.1097\/QAD.0000000000002394.","journal-title":"Aids"},{"key":"6312_CR11","unstructured":"World Health Organization. HIV drug resistance report. 2019. [R\/OL]. https:\/\/www.who.int\/hiv\/pub\/drugresistance\/hivdr-report-2019\/en\/. Accessed 15 Dec 2019."},{"key":"6312_CR12","doi-asserted-by":"publisher","first-page":"100238","DOI":"10.1016\/j.eclinm.2019.100238","volume":"18","author":"L Zuo","year":"2020","unstructured":"Zuo L, Liu K, Liu H, Hu Y, Zhang Z, Qin J, et al. Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001-2017). EClinicalMedicine. 2020;18:100238. https:\/\/doi.org\/10.1016\/j.eclinm.2019.100238.","journal-title":"EClinicalMedicine"},{"issue":"10","key":"6312_CR13","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1089\/aid.2010.0119","volume":"27","author":"B Zhao","year":"2011","unstructured":"Zhao B, Han X, Dai D, Liu J, Ding H, Xu J, et al. New trends of primary drug resistance among HIV type 1-infected men who have sex with men in Liaoning Province, China. AIDS Res Hum Retrovir. 2011;27(10):1047\u201353. https:\/\/doi.org\/10.1089\/aid.2010.0119.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"Suppl 1","key":"6312_CR14","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1097\/QAI.0b013e3181c7d5bf","volume":"53","author":"X Han","year":"2010","unstructured":"Han X, Dai D, Zhao B, Liu J, Ding H, Zhang M, et al. Genetic and epidemiologic characterization of HIV-1 infection in Liaoning Province, China. J Acquir Immune Defic Syndr. 2010;53(Suppl 1):S27\u201333. https:\/\/doi.org\/10.1097\/QAI.0b013e3181c7d5bf.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"6312_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/QAI.0b013e3182932210","volume":"64","author":"X Han","year":"2013","unstructured":"Han X, An M, Zhang M, Zhao B, Wu H, Liang S, et al. Identification of 3 distinct HIV-1 founding strains responsible for expanding epidemic among men who have sex with men in 9 Chinese cities. J Acquir Immune Defic Syndr. 2013;64(1):16\u201324. https:\/\/doi.org\/10.1097\/QAI.0b013e3182932210.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"22","key":"6312_CR16","doi-asserted-by":"publisher","first-page":"12402","DOI":"10.1128\/JVI.00262-12","volume":"86","author":"M An","year":"2012","unstructured":"An M, Han X, Xu J, Chu Z, Jia M, Wu H, et al. Reconstituting the epidemic history of HIV strain CRF01_AE among men who have sex with men (MSM) in Liaoning, northeastern China: implications for the expanding epidemic among MSM in China. J Virol. 2012;86(22):12402\u20136. https:\/\/doi.org\/10.1128\/JVI.00262-12.","journal-title":"J Virol"},{"issue":"3","key":"6312_CR17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/QAI.0000000000000467","volume":"68","author":"B Zhao","year":"2015","unstructured":"Zhao B, Han X, Xu J, Hu Q, Chu Z, Zhang J, et al. Increase of RT-related transmitted drug resistance in non-CRF01_AE among HIV type 1-infected men who have sex with men in the 7 cities of China. J Acquir Immune Defic Syndr. 2015;68(3):250\u20135. https:\/\/doi.org\/10.1097\/QAI.0000000000000467.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"6312_CR18","first-page":"111","volume":"24","author":"NCAIDS, NCSTD, CDC C","year":"2018","unstructured":"NCAIDS, NCSTD, CDC C. Update on the AIDS\/STD epidemic in China and main response in control and prevention in October, 2017. Chin J AIDS STD. 2018;24(2):111.","journal-title":"Chin J AIDS STD"},{"issue":"1","key":"6312_CR19","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1186\/s12879-019-4355-y","volume":"19","author":"H Wang","year":"2019","unstructured":"Wang H, Zhang Y, Mei Z, Jia Y, Leuba SI, Zhang J, et al. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP). BMC Infect Dis. 2019;19(1):721. https:\/\/doi.org\/10.1186\/s12879-019-4355-y.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"6312_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009490","volume":"5","author":"MN Price","year":"2010","unstructured":"Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees for large alignments. PLoS One. 2010;5(3):e9490.","journal-title":"PLoS One"},{"key":"6312_CR21","volume-title":"Maxim HIV-1 Limiting Antigen Avidity EIA: Single Well Avidity Enzyme Immunoassay for Detection of Recent HIV-1 Infection, Cat. No. 92001","author":"Maxim Biomedical","year":"2013","unstructured":"Maxim Biomedical. Maxim HIV-1 Limiting Antigen Avidity EIA: Single Well Avidity Enzyme Immunoassay for Detection of Recent HIV-1 Infection, Cat. No. 92001; 2013. Available from: http:\/\/www.maximbio.com\/img\/insert\/920013-Product-Insert.pdf."},{"issue":"6","key":"6312_CR22","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2174\/157016211798038597","volume":"9","author":"R Granich","year":"2011","unstructured":"Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, Vitoria M, et al. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res. 2011;9(6):446\u201369. https:\/\/doi.org\/10.2174\/157016211798038597.","journal-title":"Curr HIV Res"},{"issue":"11\u201312","key":"6312_CR23","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/sj.cr.7290362","volume":"15","author":"FJ Zhang","year":"2005","unstructured":"Zhang FJ, Pan J, Yu L, Wen Y, Zhao Y. Current progress of China's free ART program. Cell Res. 2005;15(11\u201312):877\u201382. https:\/\/doi.org\/10.1038\/sj.cr.7290362.","journal-title":"Cell Res"},{"issue":"19","key":"6312_CR24","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1097\/00029330-200610010-00002","volume":"119","author":"Chinese Medical A","year":"2006","unstructured":"Chinese Medical A, Chinese Center for Disease C, Prevention. Guidelines for diagnosis and treatment of HIV\/AIDS in China (2005). Chin Med J. 2006;119(19):1589\u2013608.","journal-title":"Chin Med J"},{"issue":"10","key":"6312_CR25","first-page":"629","volume":"29","author":"Association APGSoIDCM","year":"2011","unstructured":"Association APGSoIDCM. Guidelines for diagnosis and treatment of HIV\/AIDS in China (2011). Chin J Infect Dis. 2011;29(10):629\u201340.","journal-title":"Chin J Infect Dis"},{"key":"6312_CR26","volume-title":"958,000 survivors were reported in China, and the AIDS epidemic is at a low level","author":"BY W","year":"2019","unstructured":"BY W, MM L, XJ B. 958,000 survivors were reported in China, and the AIDS epidemic is at a low level. 2019. http:\/\/www.xinhuanet.com\/politics\/2019-12\/01\/c_1125295336.htm."},{"key":"6312_CR27","unstructured":"National Health Commission of the People's Republic of China: Regular press conference: Progress in the prevention and treatment of AIDS in China. http:\/\/ncaids.chinacdc.cn\/xxgx\/yqxx\/201811\/t20181123_197488.htm. Accessed 19 Oct 2019."},{"issue":"11","key":"6312_CR28","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1086\/503914","volume":"42","author":"TF Liu","year":"2006","unstructured":"Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608\u201318. https:\/\/doi.org\/10.1086\/503914.","journal-title":"Clin Infect Dis"},{"key":"6312_CR29","first-page":"12","volume-title":"National free AIDS antiviral treatment manual [M]","author":"Press NfAatmctBPsH","year":"2005","unstructured":"Press NfAatmctBPsH. National free AIDS antiviral treatment manual [M]; 2005. p. 12\u20131."},{"issue":"3","key":"6312_CR30","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/infdis\/jit189","volume":"208","author":"ME Cong","year":"2013","unstructured":"Cong ME, Mitchell J, Sweeney E, Bachman S, Hanson DL, Heneine W, et al. Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian\/human immunodeficiency virus containing the K65R mutation in macaques. J Infect Dis. 2013;208(3):463\u20137. https:\/\/doi.org\/10.1093\/infdis\/jit189.","journal-title":"J Infect Dis"},{"issue":"8","key":"6312_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11908-019-0685-6","volume":"21","author":"VE Powell","year":"2019","unstructured":"Powell VE, Gibas KM, DuBow J, Krakower DS. Update on HIV Preexposure prophylaxis: effectiveness, drug resistance, and risk compensation. Curr Infect Dis Rep. 2019;21(8):28. https:\/\/doi.org\/10.1007\/s11908-019-0685-6.","journal-title":"Curr Infect Dis Rep"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06312-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06312-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06312-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T08:04:26Z","timestamp":1625817866000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06312-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6312"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06312-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2021,7,9]]},"assertion":[{"value":"12 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of The First Affiliated Hospital, China Medical University. In addition, written informed consents were obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. (This manuscript did not contain any person\u2019s data in any form).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"668"}}